We showed that Tocilizumab (TCZ), an FDA-approved anti-IL-6R antibody for the treatment of patients with rheumatoid arthritis, could reverse tamoxifen resistance in vitro and in vivo (Figure 5). The gene discussed is IL6R; the disease is rheumatoid arthritis.